Medicines As An Alternative Therapy For Covid-19

Nur Islami Fahmi, Santi Sinala, Ida Adhayanti, Sisilia Teresia Rosmala Dewi

Abstract


The coronavirus who that causes Covid-19 first appeared in Wuhan Distric, China, in December 2019, and has been a pandemic to date. In addition to the increasing prevalence of Covid-19 deaths, there are also several Covid-19 patients who have recovered. As we know that until now there is no single drug specifically for the treatment of Covid-19, so the reuse of available drugs is still carried out as an alternative. However, all these alternative medicines are still in the form of trial and error until now. The purpose of the research in this study is to find out what drugs have become alternatives for therapy in current Covid-19 patients. The method used in this research is literature study by collecting data from various scientific journals through various databases. From this research, after reviewing 12 journals. Drugs used as alternative treatments for Covid-19 patients that have been scientifically proven based on several literature studies include, Favipiravir, Remdesivir, Azithromycin, Levofloxacin, and several supporting nutrients namely Vitamin C, Vitamin E and Vitamin D.


Full Text:

PDF

References


Ali, N. (2020). Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of Infection and Public Health, 13(10), 1373–1380. https://doi.org/10.1016/j.jiph.2020.06.021

Andreani et al., (2020). Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial PRINCIPLE Trial Collaborative Group. Lancet 2020;397: 1063–74 Published Online March 4, 2021 https://doi.org/10.1016/ S0140-6736(21)00461-X See Comment page 1036

Beigel, J., (2020). Remdesivir for the treatment of covid-19-final report, on november 2020, vol. 383. No. 19 : England

Bleyzac, N., Goutelle, S., Bourguignon, L., & Tod, M. (2020). Azithromycin for COVID-19: More Than Just an Antimicrobial? Clinical Drug Investigation, 40(8), 683–686. https://doi.org/10.1007/s40261-020-00933-3

Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., … Liu, L. (2020). Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering, 6(10), 1192–1198. https://doi.org/10.1016/j.eng.2020.03.007

Dabbous, H. M., Abd-Elsalam, S., El-Sayed, M. H., Sherief, A. F., Ebeid, F. F. S., El Ghafar, M. S. A., Soliman, S., Elbahnasawy, M., Badawi, R., & Tageldin, M. A. (2021). Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Archives of Virology, 166(3), 949–954. https://doi.org/10.1007/s00705-021-04956-9

Hiedra et al., (2020) The use of IV vitamin C for patients with COVID-19: a case series. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY https://doi.org/10.1080/14787210.2020.1794819

Inoue, H., Jinno, M., Ohta, S., Kishino, Y., Kawahara, T., Mikuni, H., Sato, H., Yamamoto, M., Sato, Y., Onitsuka, C., Goto, Y., Ikeda, H., Sato, H., Uno, T., Uchida, Y., Kimura, T., Miyata, Y., Hirai, K., Homma, T., … Sagara, H. (2020). Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respiratory Medicine Case Reports, 31, 101200. https://doi.org/10.1016/j.rmcr.2020.101200

Karampela, I., & Dalamaga, M. (2020). Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? January.

McCreary & Pogue. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. http://science.sciencemag.org,on November 5,2020

Neldi, V., & Suharjono, S. (2020). Remdesivir : Mechanism and Effectiveness for Coronavirus Disease. 7, 39–48.

Pawar, A. Y. (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . January.

Olender Susan. A. et al., (2020). Remdesivir for severe covid-19 versus a cohort receiving standard of care. Division of infectious disease, Department of internal medicine. Columbia University Irving Medical Center : New York, USA

Scroggs, S. L. P., Offerdahl, D. K., Flather, D. P., Morris, C. N., Kendall, B. L., Broeckel, R. M., Beare, P. A., & Bloom, M. E. (2021). against SARS-CoV-2 and MERS-CoV. 1–12.

Shakoor, H., Feehan, J., Al Dhaheri, A. S., Ali, H. I., Platat, C., Ismail, L. C., Apostolopoulos, V., & Stojanovska, L. (2021). Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19? Maturitas, 143(July 2020), 1–9. https://doi.org/10.1016/j.maturitas.2020.08.003

World Health Organization. (2020). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Who, 2019(January), 12. https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected%0Ahttp://apps.who.int/iris/bitstream/10665/178529/1/WHO_MERS_Clinical_15.1_eng.pdf




DOI: https://doi.org/10.32382/uh.v3i1.2479

Refbacks

  • There are currently no refbacks.